New Tool: ProSource
Checkout our packaging and processing solutions finder.
Start Your Search

FDA Approves First Biologic for Kids with Eczema

The subcutaneous injection is intended for patients 6 months to 5 years affected by atopic dermatitis.

Sanofi
Sanofi

Atopic dermatitis, aka eczema, affects more than 10% of Americans of all ages. It’s characterized by inflammation that causes dry, itchy patches on the skin. Though not life-threatening, it can be a painful nuisance and lead to dermal infections. According to a recent Everyday Health article, the FDA just approved the first biologic intended to treat the condition in kids ages 6 months to 5 years.

The drug, Sanofi’s Dupixent, is administered as a monthly injection under the skin at different sites. More than half the kids who participated in the drug’s trial saw a 75% reduction in the severity of the disease. 

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts